A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity

Pharmacol Biochem Behav. 2019 Aug:183:72-79. doi: 10.1016/j.pbb.2019.06.005. Epub 2019 Jun 14.

Abstract

One of most formidable problems in the treatment of addiction is the high rate of relapse. The discovery of medicines to help mitigate relapse are aided by animal models that currently involve weeks of training and require surgical preparations and drug delivery devices. The present set of experiments was initiated to investigate a rapid 8-day screening method that utilizes food instead of intravenous drug administration. Male Sprague-Dawley rats were trained in a reinstatement paradigm in which every lever press produced a 45 mg food pellet concurrently paired with a light and tone. Behavior was subsequently extinguished with lever responses producing neither food nor food-associated stimuli. Reinstatement of responding was evaluated under conditions in which the first three responses of every 5 min time bin produced a food pellet along with food-associated stimuli. The mGlu5 receptor antagonists MPEP and MTEP produced a significant reduction in reinstatement while failing to alter responding where every response produced food. The cannabinoid CB1 receptor antagonist rimonabant and the mGlu2/3 receptor agonist LY379268 also selectively reduced reinstatement. Other compounds including clozapine, d-amphetamine, chlordiazepoxide, ABT-431, naltrexone and citalopram were without effect. The results suggest that relapse-like behavioral effects can be extended to non-pharmacological reinforcers. Drug effects demonstrated both behavioral and pharmacological specificity. The present experimental design thus allows for efficient and rapid assessment of the effects of drugs that might be useful in the treatment of addiction-associated relapse.

MeSH terms

  • Amino Acids / administration & dosage
  • Amino Acids / pharmacology
  • Animals
  • Behavior, Addictive / drug therapy*
  • Behavior, Addictive / psychology*
  • Behavior, Animal / drug effects*
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Cannabinoid Receptor Antagonists / administration & dosage
  • Cannabinoid Receptor Antagonists / pharmacology
  • Conditioning, Operant / drug effects
  • Drug Discovery / methods*
  • Excitatory Amino Acid Agonists / administration & dosage
  • Excitatory Amino Acid Agonists / pharmacology
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology
  • Extinction, Psychological / drug effects
  • Feeding Behavior / drug effects
  • Male
  • Models, Animal*
  • Pyridines / administration & dosage
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Recurrence
  • Rimonabant / administration & dosage
  • Rimonabant / pharmacology
  • Self Administration
  • Substance-Related Disorders / drug therapy
  • Thiazoles / administration & dosage
  • Thiazoles / pharmacology

Substances

  • 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine
  • Amino Acids
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cannabinoid Receptor Antagonists
  • Excitatory Amino Acid Agonists
  • Excitatory Amino Acid Antagonists
  • LY 379268
  • Pyridines
  • Thiazoles
  • 6-methyl-2-(phenylethynyl)pyridine
  • Rimonabant